This is the authors' abstract. We don't add key points for this paper.
HCV NAT-negative recipients can be safely and successfully transplanted with HCV NAT-positive donor kidneys outside of a research protocol. Access to DAA and timely administration of therapy is important and an insurance approval process within the transplant center can be beneficial to patients. A case of mixed-genotype infection was presented, and although not as common, can be successfully treated. HCV organs can expand the organ pool and should no longer be considered experimental. The use of these organs in HCV-negative recipient's decreases waiting time, have excellent outcomes, and should be considered standard of care.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jandovitz et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: